Drug Approval | December 26, 2023
Wainua granted first-ever regulatory approval in the US for improving neuropathy impairment
US FDA approval based on NEURO-TTRansform Phase III results
US FDA approval based on NEURO-TTRansform Phase III results
NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
Subscribe To Our Newsletter & Stay Updated
